\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Exploring Medicinal Plants for Anti-Helicobacter Pylori Activity}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2012-04-08 (revised: 08 April 2012)} \def\TheID{\makeatother } \def\TheDate{2012-04-08} \title{Exploring Medicinal Plants for Anti-Helicobacter Pylori Activity} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Mohammed Ibrahim} \affil[1]{ } \renewcommand\Authands{ and } \date{\small \em Received: 2 March 2012 Accepted: 24 March 2012 Published: 8 April 2012} \maketitle \begin{abstract} Helicobacter pylori isa class 1 carcinogen that requires targeted therapeutic strategy. A number of drugs including proton pump inhibitors, antibiotics and antiprotozoals are available for the treatment of Helicobacter pylori infections like chronic gastric irritation, gastro duodenal ulcers and low grade gastric mucosa associated lymphoid tissue lymphoma. Clinical evaluation of these drugs has shown the incidence of relapses, side effects and drug interactions. Multi drug resistance to Helicobacter pylori has been the main reason for treatment failure. This has been the rationale for the development of new anti- Helicobacter pylori drugs and search for novel molecules has been extended to medicinal herbs that offer better protection, decreased relapse and undevelopment of resistance towards bacteria. The present article reviews the medicinal herbs from global perspective for their anti- Helicobacter pylori activity and active compounds from the plants responsible for this activity. We have highlighted some of the important plants and their active constituents reported for their anti- Helicobacter pylori activity. Ancient system of medicine (Ayurvedic and Unani) supported by modern science is necessary to isolate, characterize and standardize the active constituents from herbal sources for anti-Helicobacter pylori activity. \end{abstract} \keywords{} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{Exploring Medicinal Plants for Anti-Helicobacter Pylori Activity}]{Exploring Medicinal Plants for Anti-Helicobacter Pylori Activity}\par Abstract -Helicobacter pylori is a class 1 carcinogen that requires targeted therapeutic strategy. A number of drugs including proton pump inhibitors, antibiotics and antiprotozoals are available for the treatment of Helicobacter pylori infections like chronic gastric irritation, gastro duodenal ulcers and low grade gastric mucosa associated lymphoid tissue lymphoma. Clinical evaluation of these drugs has shown the incidence of relapses, side effects and drug interactions. Multi drug resistance to Helicobacter pylori has been the main reason for treatment failure. This has been the rationale for the development of new anti-Helicobacter pylori drugs and search for novel molecules has been extended to medicinal herbs that offer better protection, decreased relapse and undevelopment of resistance towards bacteria. The present article reviews the medicinal herbs from global perspective for their anti-Helicobacter pylori activity and active compounds from the plants responsible for this activity. We have highlighted some of the important plants and their active constituents reported for their anti-Helicobacter pylori activity. Ancient system of medicine (Ayurvedic and Unani) supported by modern science is necessary to isolate, characterize and standardize the active constituents from herbal sources for anti-Helicobacter pylori activity.\par Health Organization has categorized H. pylori as a class 1 carcinogen. \hyperref[b4]{5} Eradication of the organism has been shown to result in ulcer healing, prevention of peptic ulcer reoccurrence and may also reduce the prevalence of gastric cancer in high-risk populations. \hyperref[b5]{6} Many clinical trails involving patients with gastric and duodenal ulcers show that curing the infection is associated with a significant reduction in ulcer reoccurrence rates. \hyperref[b6]{[7]}\hyperref[b7]{[8]} Since 1984 physicians prescribing triple therapy to treat H. pylori infections which includes three options.\par First option includes the combination of proton pump inhibitor (PPI), clarithromycin and ampicillin. Second option includes PPI, clarithromycin and metronidazole. Third option includes bismuth subsalicylate, metronidazole and tetracycline, but the cure rate from standard triple therapy has been low as 50\%. 9-10 However, eradication by the triple therapy is not always successful and acquisition by H. pylori resistance to antibiotics could present a serious problem that may reduce treatment efficiency. \hyperref[b11]{11} Quadruple therapy, where three antibiotics are taken alongside the PPI, has also been used in cases where triple therapy has not been successful. But the success rate was only 67\%. \hyperref[b12]{12} Many strains of H. pylori are now developing resistance to commonly used antibiotics. H. pylory acquires resistance by mutations to all the antibiotics used in the treatment regimens. The mechanism of resistance involves point mutations which are transmitted vertically, however transformation may be possible if two strains are present simultaneously in the stomach. Drug efflux proteins also can contribute to natural insensitivity to antibiotics and to emerging antibiotic resistance. Efflux pump gene hef A of H. pylori play an important role in multidrug resistance. Global resistance of H. pylori to metronidazole, clarithromycin, amoxicillin and tetracycline was also reported. One person may have more than one strain of H. pylori. Here the antibiotics may kill one strain, but not the other. \hyperref[b14]{[13]}\hyperref[b15]{[14]} Furthermore, undesirable side effects of the drugs and the significant cost of combination therapy require the \section[{Global Journal of Medical Research Volume XII Issue IV Version I}]{Global Journal of Medical Research Volume XII Issue IV Version I}\par elicobacter pylori (H. pylori), a Gram -negative 1984 by Marshall et al, is one of the most common chronic bacterial pathogens in humans. 1 Approximately 50\% of people in the world are infected with it, and its prevalence is significantly higher in developing countries than in developed countries. \hyperref[b1]{2} Once a person is infected, the organism can live in the stomach indefinitely and may not cause clinical illness. It is still not clear how H.pylori are transmitted or why some people infected with bacteria become sick and others do not. \hyperref[b2]{3} H. pylori infection is an important etiologic impetus usually leading to chronic gastritis, gastroduodenal ulcer and low grade gastric mucosa associated lymphoid tissue lymphoma.\par Epidemiological data shows that a high H. pylori infection rate is related to the high incidence of gastric cancer and gastric adenocarcinoma. \hyperref[b3]{4} World H spiral bacterium which was first detected in I. \section[{Introduction}]{Introduction}\par II.\par Current Treatment Regimens As phytomedicine has proved to be an untapped treasure for the discovery of lead compounds to cure gastrointestinal disorders. Hence several studies have been aimed to evaluate the anti-helicobacter pylori activity of medicinal herbs. \hyperref[b16]{15} To the best of our knowledge, there is no extensive global view on exploring medicinal plants for anti-helicobacter pylori activity. List of medicinal herbs with anti-Helicobacter pylori activity including their source and active extracts are given in table {\ref 1}.\par The insolubility of non-polar extracts makes it very difficult for the investigators to be used in an aqueous medium during the study of anti-Helicobacter pylori activity. \hyperref[b26]{26} Water or alcohol (methanol/ethanol) are used mainly for a large number of crude extract preparations. \hyperref[b27]{27} The type of solvent used may have an effect on the nature of the compounds extracted and the resulting bioactivity of the extract. \hyperref[b28]{28} To estimate the value of each extract therefore, several factors, including the rate of extraction, the quantity extracted (yield), the diversity of compounds extracted, the diversity of inhibitory compounds extracted, the ease of subsequent handling of the extracts, toxicity of the solvent in the bioassays and the potential health hazards of the extractants have to be evaluated. In many research works, methanol/ethanol is used for alkaloid extraction; acetone for flavonoids and steroids; hexane, diethyl ether and chloroform for fat soluble oils, wax, lipids and esters. Dichloromethane for terpenoids, ethylacetate for esters, ethanol may be used for sterols, poly phenols, tannins and water for water soluble components like glycosides, polysaccharides, polypeptides and lectins. \hyperref[b29]{29} Hundreds of plants with antimicrobial compounds have been reported. However, very few of these studies have reported the in vivo anti-Helicobacter pylori activity of these compounds. It is very important to know whether these compounds will still maintain their maximum activity in the gastric mucus niche of H. pylori. Anti-Helicobacter pylori compounds from plants and their mechanism of action are given in table \hyperref[tab_2]{2}.\par Curcumin, biologically active poly phenolic from Curcuma longa has recently been shown to arrest H. pylori growth. The anti-Helicobacter pylori activity of curcumin against 65 clinical isolates of H. pylori in vitro was examined. Minimum inhibitory concentration ranging from 5-50 µg/ml, showing its effectiveness against H. pylori growth in vitro irrespective of genetic makeup of strains. Curcumin showed immense therapeutic potential against H.pylori infection as it was highly effective in eradication of H.pylori from infected mice as well as restoration of H.pylori induced gastric damage.\par Curcuma longa extract was the most efficient in killing the seven strains of H.pylori within 15 minutes followed by chilli and ginger. \hyperref[b48]{[46]}\hyperref[b49]{[47]}\hyperref[b51]{[48]} Mallotus phillipinesis is (Lam) Muell. Exhibited the most potent bactericidal activity against H.pylori which completely killed the bacteria at the concentration of 15.6-31.2 µg/ml. \hyperref[b17]{16} There is no evidence of in vivo effectiveness of this plant. Antibacterial activity of Allium sativum L(garlic) against H.pylori is well documented (40 µg/ml) and resistance has not been reported.The synergistic action of garlic and omeprazole against H.pylori was also reported.\par Thiosulfinates play an important role in the antibiotic activity of garlic. Further clinical evaluation seems warranted. \hyperref[b52]{[49]}\hyperref[b53]{[50]}\hyperref[b54]{[51]} A mixture of tannic acid and n-propyl gallate can limit the gastric mucosa deterioration induced by H.pylori infection and vac A administration, suggest that vac A inhibition plays a role in this protective activity. So, polyphenols from plant sources may contribute to limit the pathological outcomes of H.pylori infection. \hyperref[b55]{52} Successive extracts of Sapindus mukorossi and Rheum emodi inhibited the growth of 30 resistant clinical isolates of H.pylori in vitro and in vivo studies and there was no acquired resistance against these herbal extracts even after ten consecutive passages. \hyperref[b56]{53} The evidence summarized above tentatively suggests possible benefits from some herbal sources with anti-Helicobacter pylori activity. Herbal science, Ayurvedic knowledge supported by modern science is required to standardize the plant extracts and to isolate, characterize and standardize the active constituents from plant sources for anti-Helicobacter pylori activity.\par Extensive investigations and large scale well designed clinical trails are required to provide more conclusive proof to explore medicinal herbs for anti-Helicobacter pylori activity.\par Table1 : Medicinal herbs having anti-Helicobacter pylori activity (global perspective). \section[{Global Journal of}]{Global Journal of}\begin{figure}[htbp] \noindent\textbf{4}\includegraphics[]{image-2.png} \caption{\label{fig_0}hydroxy- 4}\end{figure} \begin{figure}[htbp] \noindent\textbf{} \par \begin{longtable}{P{0.4604659248956884\textwidth}P{0.14895688456189152\textwidth}P{0.15073018080667594\textwidth}P{0.07093184979137691\textwidth}P{0.018915159944367176\textwidth}} \multicolumn{4}{l}{Exploring Medicinal Plants for Anti-Helicobacter Pylori Activity}\tabcellsep \\ Botanical name\tabcellsep Source\tabcellsep Part used\tabcellsep Extract\tabcellsep Reference\\ South Asian Herbs\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Mallotus phillipinesis\tabcellsep Pakistan\tabcellsep covering fruit\tabcellsep Aqueous ethanol (70\%)\tabcellsep 16,17,18\\ Curcuma amada Roxb.\tabcellsep Pakistan\tabcellsep rhizome\tabcellsep \tabcellsep \\ Myristica fragrans Houtt.\tabcellsep Pakistan\tabcellsep seed\tabcellsep \tabcellsep \\ Psoralea corylifolia\tabcellsep Pakistan\tabcellsep seed\tabcellsep \tabcellsep \\ Glycyrrhiza glabra L\tabcellsep India,Srilanka\tabcellsep root\tabcellsep \tabcellsep \\ Terminalia chebula\tabcellsep Pakistan\tabcellsep fruit\tabcellsep \tabcellsep \\ Curcuma longa L\tabcellsep India\tabcellsep rhizome\tabcellsep \tabcellsep \\ Cuminum cyminum\tabcellsep Srilanka\tabcellsep seed\tabcellsep \tabcellsep \\ Coccinia grandis\tabcellsep India\tabcellsep leaves\tabcellsep Ethanol\tabcellsep \\ Terminalia arjuna\tabcellsep India\tabcellsep bark\tabcellsep Methanol\tabcellsep \\ East Asian Herbs\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Rhizoma coptidis\tabcellsep China\tabcellsep rhizome\tabcellsep Aqueous\tabcellsep 19,20\\ Radix scutellariae\tabcellsep China\tabcellsep root\tabcellsep \tabcellsep \\ Radix isatidis Asasarum sieboldi\tabcellsep China Korea\tabcellsep root root\tabcellsep Methanol\tabcellsep \\ Lindera strychifolia\tabcellsep Korea\tabcellsep root\tabcellsep \tabcellsep \\ Angelica tenuissima\tabcellsep Korea\tabcellsep root\tabcellsep \tabcellsep \\ Alpinia oxyphylla\tabcellsep Korea\tabcellsep fruit\tabcellsep \tabcellsep \\ American Herbs\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Zingiber officinale\tabcellsep USA\tabcellsep rhizome\tabcellsep Methanol\tabcellsep 21\\ Rosmarinus officinalis\tabcellsep USA\tabcellsep rosemary leaf\tabcellsep \tabcellsep \\ Foeniculum vulgare\tabcellsep USA\tabcellsep seed\tabcellsep \tabcellsep \\ Nigella sativa\tabcellsep USA\tabcellsep seed\tabcellsep \tabcellsep \\ African Herbs\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Terminalia spinosa\tabcellsep East Africa\tabcellsep young branches\tabcellsep Aqueous\tabcellsep 22\\ Harrisonia abyssinica\tabcellsep East Africa\tabcellsep root\tabcellsep \tabcellsep \\ Ximenia caffra\tabcellsep East Africa\tabcellsep root\tabcellsep \tabcellsep \\ Azadirachta indica\tabcellsep East Africa\tabcellsep leaves, stem bark\tabcellsep \tabcellsep \\ Combretum molle\tabcellsep South Africa\tabcellsep stem bark\tabcellsep Acetone\tabcellsep 23\\ Sclerocarya birrea\tabcellsep South Africa\tabcellsep stem bark\tabcellsep \tabcellsep \\ Carica papaya\tabcellsep Nigeria\tabcellsep leaf\tabcellsep Aqueous\& ethanol\tabcellsep 24\\ Morinda lucida\tabcellsep Nigeria\tabcellsep leaf\tabcellsep \tabcellsep \\ Octimum gratissimum Phyllanthus amarus\tabcellsep Nigeria Nigeria\tabcellsep leaf leaf\tabcellsep \tabcellsep \\ Brazelian Herbs\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Bixa orellana L\tabcellsep Brazil\tabcellsep seed\tabcellsep Aqueous ethanol (96\%)\tabcellsep 25\\ Chamonilla recutita L\tabcellsep Brazil\tabcellsep inflorescence\tabcellsep \tabcellsep \\ Ilex paraguariensis A\tabcellsep Brazil\tabcellsep green leaves\tabcellsep \tabcellsep \\ Malva sylvestris L\tabcellsep Brazil\tabcellsep inflorescence \& leaves\tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_1}}\end{figure} \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{P{0.2770509977827051\textwidth}P{0.1319290465631929\textwidth}P{0.3637472283813747\textwidth}P{0.01696230598669623\textwidth}P{0.043348115299334807\textwidth}P{0.01696230598669623\textwidth}} \tabcellsep \multicolumn{4}{l}{Exploring Medicinal Plants for Anti-Helicobacter Pylori Activity}\\ \multicolumn{2}{l}{Compound name}\tabcellsep Examples\tabcellsep \tabcellsep Mechanism of action\tabcellsep reference\\ Quinones\tabcellsep \tabcellsep \multicolumn{2}{l}{Quinones,idebenone,duroquinone,}\\ \tabcellsep \tabcellsep \multicolumn{2}{l}{menadione,juglone,coenzyme Q 1}\\ \multicolumn{2}{l}{Flavones, flavonoids}\tabcellsep \multicolumn{2}{l}{Quercetin, catechins, myristin, rutin}\\ and flavonols\tabcellsep \tabcellsep \tabcellsep \\ Phenolics\tabcellsep and\tabcellsep \multicolumn{2}{l}{Catechol, pyrogallol, curcumin}\\ polyphenols\tabcellsep \tabcellsep \tabcellsep \\ Tannins\tabcellsep \tabcellsep \multicolumn{3}{l}{Polymeric phenols, hydrolysable tannins}\\ \tabcellsep \tabcellsep 7-hydroxy-4-methyl\tabcellsep coumarin,\tabcellsep 6,7-\\ Coumarins\tabcellsep \tabcellsep \tabcellsep \\ Terpenoids\tabcellsep and\tabcellsep \tabcellsep \\ essential oils\tabcellsep \tabcellsep \tabcellsep \\ Alkaloids\tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{2}{l}{Lectins and poly}\tabcellsep \tabcellsep \\ peptides\tabcellsep \tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_2}Table 2 :}\end{figure} \footnote{© 2012 Global Journals Inc. (US)} \footnote{© 2012 Global Journals Inc. (US) © 2012 Global Journals Inc. (US)} \footnote{Exploring Medicinal Plants for Anti-Helicobacter Pylori Activity} \backmatter \begin{bibitemlist}{1} \bibitem[ Hoffman JS Pharmacological therapy]{b7}\label{b7} \textit{}, \textit{Hoffman JS Pharmacological therapy} \bibitem[Zhang and Lewis ()]{b47}\label{b47} \textit{}, Y Zhang , K F Lewis . \textit{New antimicrobial plant peptides FEMS Microbiol Lett} 1997. 149 p. . \bibitem[ Helicobacterpylori: a global overview Acta Gastro-Ent Belg ()]{b11}\label{b11} \textit{}, \textit{Helicobacterpylori: a global overview Acta Gastro-Ent Belg} 1998. 61 p. . \bibitem[ Microbiol Immunol ()]{b46}\label{b46} \textit{}, \textit{Microbiol Immunol} 2000. 44 p. . \bibitem[Sapulveda et al. ()]{b5}\label{b5} \textit{}, A R Sapulveda , Lgv Coelho , Helicobacterpylori . \textit{Helicobacter} 2002. 7 (1) p. . \bibitem[ Anticancer Res ()]{b50}\label{b50} \textit{}, \textit{Anticancer Res} 2002. 22 p. . \bibitem[ Antimicrobial Agents Chemother ()]{b42}\label{b42} \textit{}, \textit{Antimicrobial Agents Chemother} 2005. 49 p. . \bibitem[ Helicobacter ()]{b13}\label{b13} \textit{}, \textit{Helicobacter} 2007. 12 p. . \bibitem[Torres et al. ()]{b15}\label{b15} ‘A comprehensive review of the natural history of Helicobacter pylori infection in children’. J Torres , G Perez-Perez , K J Goodman , J C Atherton , B D Gold , P R Harris , Ia Garza , A M Guaner , J Munoz , O . \textit{Arch Med Res} 2000. 31 p. . \bibitem[Lee and Lee ()]{b20}\label{b20} ‘Ahn YJ Antibacterial activity of oriental medicinal plants extracts toward Helicobacter pylori’. H B Lee , H K Lee . \textit{Agri Chem Biotechnol} 2003. 46 (3) p. . \bibitem[Hughes and Lawson ()]{b54}\label{b54} ‘Allium ampeloprasum (elephant garlic) and Allium cepa (onion), garlic compounds and commercial garlic supplement products’. B G Hughes , L D Lawson . \textit{Phytotherapy Res} 1991. 5 p. . (Antimicrobial effect of Allium sativum L (garlic)) \bibitem[Fabry and Okemo ()]{b22}\label{b22} ‘Ansorg R Activity of East African medicinal plants against Helicobacter pylori’. W Fabry , P Okemo . \textit{Chemotherapy} 1996. 42 (5) p. . \bibitem[Funatogawa et al. ()]{b39}\label{b39} ‘Antibacterial activity of hydrilysable tannins derived from medicinal plants against Helicobacter pylori’. K Funatogawa , H Shunji , S Hirofumi , Y Takashi , H Tsutomu , H Yashikazu . \textit{Microbiol Immunol} 2004. 48 p. . \bibitem[De et al. ()]{b51}\label{b51} ‘Antimicribial activity of curcumin against Indian Helicobacter pylori and also during mice infection’. Ronita De , P Kundu , S Snehasikta , T Ramamurthy , C Abhijit , Balakrishna Nair , G , Ashis Mukhopadhyay . \textit{Antimicrobial agents and Chemotherapy} 2009. 53 (4) p. . \bibitem[Basile et al. ()]{b43}\label{b43} ‘Antimicrobial and antioxidant activities of coumarins from the roots of Ferulago campestris (Apiaceae)’. A Basile , S Sorbo , V Spadaro , M Bruno , A Maggio , N Faroano , S Rosselli . \textit{Molecules} 2009. 14 p. . \bibitem[Zaidi et al. ()]{b17}\label{b17} ‘Bactericidal activity of medicinal plants, employed for the treatment of gastrointestinal ailments against Helicobacter pylori’. Sfh Zaidi , K Yamada , M Kadowaki , K Usmanghani , T Sugiyama , R O Mahony , H A Khutheeri , D Weerasekera , N Fernando , D Vaira . \textit{J Ethanopharmacol} 2009. 2005. 121 (47) p. . (W J Gastroenter) \bibitem[Kivi et al. ()]{b14}\label{b14} ‘Befrits R Concordance of Helicobacter pylori strains within families’. M Kivi , Y Tindberg , M Sorberg , T H Casswall . \textit{J Clin Microb} 2003. 41 (12) p. . \bibitem[Bussing A Induction of apoptosis by the mistletoe lectins: A review on the mechanism of cytotoxicity References Références Referencias 2012 May mediated by Viscum album Apoptosis ()]{b29}\label{b29} ‘Bussing A Induction of apoptosis by the mistletoe lectins: A review on the mechanism of cytotoxicity References Références Referencias 2012 May mediated by Viscum album’. \textit{Apoptosis} 1996. 1 p. . \bibitem[Mhady et al. ()]{b21}\label{b21} ‘Chadwich LR Invitro susceptibility of Helicobacter pylori to botonical extracts used traditionally for the treatment of gastrointestinal disorders’. G B Mhady , S L Pendland , A Stoia , F A Hamill , D Fabricant , B M Dietz . \textit{Phytother Res} 2005. 19 (11) p. . \bibitem[Kawase et al. ()]{b40}\label{b40} \textit{Chatterjee SS Structural requirements of hyroxylated coumarins for in vitro anti-Helicobacter pylori activity: In vivo}, M Kawase , T Tanaka , Y Sohara , S Tani , H Sakagami , H Haver . 2003. 17 p. . \bibitem[Bergonzelli et al. ()]{b44}\label{b44} ‘Corthesy-Jheulaz IE Essential oils as components of a diet-based approach to management of Helicobacter pylori’. P O Bergonzelli , L O Chikwelu , D Dannicola , N Porta . \textit{Antimicrob Agents Chemoth} 2003. 47 p. . \bibitem[Cowan MM Plant products as Antimicrobial agents Clin Microbiol Rev ()]{b30}\label{b30} ‘Cowan MM Plant products as Antimicrobial agents’. \textit{Clin Microbiol Rev} 1999. 12 p. . \bibitem[Mahandy et al.]{b49}\label{b49} \textit{Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori}, G B Mahandy , S L Pendland , G Yung , Luzz Turmeric . (a group 1 carcinogen) \bibitem[Usta and Saltik-Temizel ()]{b9}\label{b9} ‘Derim H Comparison of short and long term treatment protocols and the results of second-line quadrupole therapy in children with Helicobacter pylori infection’. Y Usta , I N Saltik-Temizel . \textit{J Gastroenterol} 2008. 43 p. . \bibitem[Eloff JN Which extractant should used for the screening and isolation of antimicrobial components from plants J Ethanopharmacol ()]{b28}\label{b28} ‘Eloff JN Which extractant should used for the screening and isolation of antimicrobial components from plants’. \textit{J Ethanopharmacol} 1998b. 60 p. . \bibitem[Ustun et al. ()]{b33}\label{b33} ‘Flavonoids with anti-Helicobacter pylori activity from Citus laurifolius leaves’. O Ustun , O Berrin , A Yakut , A Ufuk , Y Erdem . \textit{J Ethanopharmacol} 2006. 108 p. . \bibitem[Howden and Hunt ()]{b6}\label{b6} ‘Guidelines for management of Helicobacter pylori infection’. C W Howden , R H Hunt . \textit{Am J Gastroenterology} 1998. 93 p. . \bibitem[Cogo et al. ()]{b25}\label{b25} ‘Helicobacter pylori activity of plant extracts traditionally used for the treatment of gastrointestinal disorders’. L L Cogo , Clb Monteiro , M D Miguel , O G Miguel , M M Cunico , M L Ribeeiro , Anti . \textit{Brazilian J Microbiol} 2010. 41 p. . \bibitem[Gaby ()]{b10}\label{b10} ‘Helicobacter pylori eradication: are there alternatives to antibiotics’. A R Gaby . \textit{Altern Med Rev} 2001. 6 (4) p. . \bibitem[Helicobacterpylori infection Semin Gastrointest Dis ()]{b8}\label{b8} ‘Helicobacterpylori infection’. \textit{Semin Gastrointest Dis} 1997. 8 p. . \bibitem[Hamasaki et al.]{b45}\label{b45} \textit{Highly selective antibacterial activity of novel alkyl quinolone alkaloid from a chinese herbal medicine against Helicobacter pylori in vitro}, N Hamasaki , E Ishile , K Taniinga , Y Tezuka , J Nagaoka . \bibitem[Pellecure et al. ()]{b26}\label{b26} \textit{Huiles essentielles bactericide et fongicides. Revue del L institute pasteur de lyon}, S Pellecure , J Allegrini , S Bouchberg . 1976. 9 p. . \bibitem[IARC working groups on the evaluation of carcinogenic risk to humans. Schistosomes, liver flukes and Helicobacterpylori Lyon ()]{b4}\label{b4} \textit{IARC working groups on the evaluation of carcinogenic risk to humans. Schistosomes, liver flukes and Helicobacterpylori Lyon}, 1994. 61 p. . \bibitem[Ibrahim et al.]{b56}\label{b56} M D Ibrahim , A K Aleem , K T Santosh , M A Habeeb , M N Khaja . \textit{Habibullah CM Antimicrobial activity of Sapindus mukorossi and Rheum emodi extracts against H.pylori: In vitro and In vivo studies}, \bibitem[Inatsu et al. ()]{b32}\label{b32} ‘Idebenone acts against growth of Helicobacter pylori by inhibiting its respiration’. S Inatsu , O Ayumi , N Kumiko . \textit{Antimicrob Agents Chemother} 2006. 50 p. . \bibitem[Baldari et al. ()]{b2}\label{b2} ‘Immune subversion by Helicobacterpylori’. C T Baldari , A Lanzavecchia , J L Telford . \textit{Trends Immunol} 2005. 26 p. . \bibitem[Herrling et al. ()]{b31}\label{b31} ‘Important role of melanin as protector against free radicals in skin’. T Herrling , K Jung , J Fuches . \textit{SOFWJ} 2007. 133 p. . \bibitem[Masam and Wasserman ()]{b35}\label{b35} ‘Inactivation of red beet ?-glycon synthase by native and oxidized phenolic compounds’. T L Masam , B P Wasserman . \textit{Phytochemistry} 1987. 26 p. . \bibitem[Mario et al. ()]{b48}\label{b48} ‘Iori V A Curcumin based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure’. Di Mario , F Cavallaro , L G Nouvenne , A Stefani , N Cavestro , GM . \textit{Helicobacter} 2007. 12 p. . \bibitem[Eloff and Katerere ()]{b27}\label{b27} ‘McGaw LJ The biological activity and chemistry of the Southren African Combretaceae’. J N Eloff , D R Katerere . \textit{J Ethanopharmacol} 2008. 119 p. . \bibitem[Njume and Jide ()]{b23}\label{b23} ‘Ndip RN Aqueous and organic extracts of selected South African medicinal plants possesss antimicrobial activity against drug resistant strains of Helicobacter pylori inhibition and bactericidal potential’. C Njume , A L Jide . \textit{Int J Mol Sci} 2011. 12 (9) p. . \bibitem[NIH consenses conference Helicobacterpylori in peptic ulcer disease Jamaica ()]{b3}\label{b3} ‘NIH consenses conference Helicobacterpylori in peptic ulcer disease’. \textit{Jamaica} 1994. 272 p. . \bibitem[Goodwin and Mendall ()]{b1}\label{b1} ‘Northfield TC Helicobacterpylori infection’. C S Goodwin , M M Mendall . \textit{Lancet} 1997. 349 p. . \bibitem[Smith et al. ()]{b24}\label{b24} ‘Omonigbehin EA The effect of some Nigerian local herbs on Helicobacter pylori’. S I Smith , K S Oyede , B Opere , B A Walokum . \textit{Afri J Clin Exp Microbiol} 2003. 4 (2) p. . \bibitem[Sivam et al. ()]{b52}\label{b52} ‘Polter JD Helicobacter pylori-in vitro susceptibility to garlic (Allium sativum) extracts’. G P Sivam , J W Lampe , B Ulness , S R Swanzy . \textit{Nutr Cancer} 1997. 27 p. . \bibitem[Ruggiero et al. ()]{b55}\label{b55} ‘Polyphenols reduce gastritis induced by Helicobacter pylori infection or vac A toxin administration in mice’. P Ruggiero , F Tombola , G Rossi , L Pancotto , L Lauretti , Del Giudice , G Zoratti , M . \textit{Antimicro agents Chemotherapy} 2006. 50 (7) p. . \bibitem[Poovendran and Kalaigandhi ()]{b18}\label{b18} ‘Poogunran D In-vitro antimicrobial activity of Coccinia grandis on ulcer producing Helicobacter pylori’. P Poovendran , V Kalaigandhi . \textit{Euro J App Sci} 2011. 3 (3) p. . \bibitem[Moore]{b41}\label{b41} \textit{Salma NR Mutational analysis metronidazole resistance in Helicobacter pylori}, J M Moore . \bibitem[Saltik-Temizel Second-Line Helicobacter pylori Therapy Eradication Failure in Children]{b12}\label{b12} \textit{Saltik-Temizel Second-Line Helicobacter pylori Therapy Eradication Failure in Children}, \bibitem[Scalbert A Antimicribial properties of tannins Phytochemistry ()]{b38}\label{b38} ‘Scalbert A Antimicribial properties of tannins’. \textit{Phytochemistry} 1991. 30 p. . \bibitem[Wang and Huang ()]{b16}\label{b16} ‘Screening of anti-helicobacter pylori herbs deriving from Taiwanese folk medicinal plants’. Y C Wang , T L Huang . \textit{FEMS-Immunol Med Microbiol} 2005. 43 p. . \bibitem[Biradar et al. ()]{b36}\label{b36} ‘Singhania SS Exploring of antimicrobial activity of Triphala Mashian Ayurvedic formulation’. Y S Biradar , J Sheetal , K R Khandelwal . \textit{Evid based Complem Alter Med} 2008. 5 p. . \bibitem[Jonkers et al. ()]{b53}\label{b53} ‘Stobberingh E Antibacterial effect of garlic and omeprazole on Helicobacter pylori’. D Jonkers , E V Brork , I Van Dooren , L Thiji , E Dirant , G Hageman . \textit{J Antimicrobial Chemotherapy} 1999. 43 p. . \bibitem[Hoste et al. ()]{b37}\label{b37} ‘The effects of tannin rich plants on parasitic nematodes in ruminates’. H Hoste , J Frank , A Spiridoula , M Stig , Soh Thamsborg . \textit{Trends Parsitol} 2006. 22 p. . \bibitem[Mabe et al. ()]{b34}\label{b34} ‘Tsuneo T In-vitro and in vivo activities of Tea catechins against Helicobacter pylori’. K Mabe , Y Masami , O Itaro . \textit{Antimicrobia Agents Chemother} 1999. 43 p. . \bibitem[Marshall and Warren ()]{b0}\label{b0} ‘Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration’. B J Marshall , J R Warren . \textit{Lancet} 1984. 1 p. . \bibitem[Ma et al. ()]{b19}\label{b19} ‘Yang Bai Screening test for anti-Helicobacter pylori activity of traditional Chinese herbal medicines’. Feng Ma , Ye Chen , Jing Li , He-Ping Qing , Ji-De Wang , Ya-Li Zhang , Bei-Guo Long . \textit{W J Gastroenter} 2010. 16 (44) p. . \end{bibitemlist} \end{document}